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participate.An Updated Bleeding Model to Predict the Risk of Post-Procedure Bleeding Among
Patients Undergoing Percutaneous Coronary Intervention: A Report Using an
Expanded Bleeding Deﬁnition From the National Cardiovascular Data Registry
CathPCI Registry897Sunil V. Rao, Lisa A. McCoy, John A. Spertus, Ronald J. Krone, Mandeep Singh,
Susan Fitzgerald, Eric D. Peterson
Pre-procedural identiﬁcation of patients undergoing percutaneous coronary inter-
vention at risk of bleeding could support more efﬁcient use of bleeding avoidance
strategies (BAS). We used data from the National Cardiovascular Data Registry
CathPCI Registry to deﬁne contemporary event rates and major predictors of
bleeding, as well as to develop and validate both a full pre-procedure risk prediction
model and a simple bedside additive risk prediction tool. We found both models to
have good operating characteristics in the overall dataset, as well as among high-risk
subgroups, thereby facilitating the use of BAS in patients most likely to beneﬁt.See additional content in the online version of this issue.CLINICAL RESEARCH Clinical Outcomes of the Resolute Zotarolimus-Eluting Stent in Patients
With In-Stent Restenosis: 2-Year Results From a Pooled Analysis905Gert Richardt, Matthias Leschke, Mohamed Abdel-Wahab, Ralph Toelg, Mohamed El-Mawardy,
Patrick W. Serruys, Sigmund Silber, Stephan Windecker, Jorge A. Belardi, Franz-Josef Neumann,
Petr Widimsky, on behalf of the RESOLUTE All Comers and RESOLUTE International
Investigators
In-stent restenosis (ISR) is associated with higher rates of revascularization
compared with de novo lesions, and data about ISR treatment with second-
generation drug-eluting stents are scarce. We performed a pooled analysis of ISR
patients treated with the Resolute zotarolimus-eluting stent (R-ZES) from 2 large
trials to assess R-ZES clinical safety and effectiveness. Two-year target lesion
revascularization and target lesion failure rates were signiﬁcantly higher in ISR
patients; however, cardiac death and myocardial infarction rates were not. Two-year
outcomes by ISR stent type (bare metal vs. drug eluting) were similar. We conclude
that the R-ZES offers an effective alternative for treating ISR.(continued on A-21)
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A-21Meta-Analysis of Everolimus-Eluting Versus Paclitaxel-Eluting Stents in Coronary
Artery Disease: Final 3-Year Results of the SPIRIT Clinical Trials Program (Clinical
Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the
Treatment of Patients With De Novo Native Coronary Artery Lesions)914George D. Dangas, Patrick W. Serruys, Dean J. Kereiakes, James Hermiller, Ali Rizvi,
William Newman, Krishnankutty Sudhir, Robert S. Smith, Jr, Sherry Cao,
Kleanthis Theodoropoulos, Donald E. Cutlip, Alexandra J. Lansky, Gregg W. Stone
We sought to compare 2 types of drug-eluting coronary stents with respect to long-
term clinical outcomes in a meta-analysis of the ﬁnal 3-year results from the
international SPIRIT (Clinical Evaluation of the Xience V Everolimus Eluting
Coronary Stent System in the Treatment of Patients With De Novo Native
Coronary Artery Lesions) II, III, and IV clinical trials. We found that coronary
implantation of an everolimus-eluting stent was superior to a paclitaxel-eluting stent
with respect to 3-year occurrence of the following individual endpoints: all-cause
mortality, myocardial infarction, stent thrombosis, ischemia-driven target lesion
revascularization, and target lesion failure.Impact of Kissing Balloon Inﬂation on the Main Vessel Stent Volume, Area,
and Symmetry After Side-Branch Dilation in Patients With Coronary Bifurcation
Lesions: A Serial Volumetric Intravascular Ultrasound Study923Shahid Rahman, Tara Leesar, Mehmet Cilingiroglu, Mohamed Effat, Imran Arif, Tarek Helmy,
Massoud A. Leesar
It remains controversial whether kissing balloon inﬂation (KBI) would restore the
main vessel (MV) stent area and symmetry loss after side-branch (SB) dilation. A
total of 88 serial intravascular ultrasound examinations of the MV were performed
after MV angioplasty, MV stenting, SB dilation, and KBI in 22 patients with
coronary bifurcation lesions. We demonstrated that KBI restored the MV stent
volume, area, and symmetry loss after SB dilation in the bifurcation segment, and
induced asymmetric stent expansion in the proximal segment.(continued on A-22)
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A-22Adjunctive Cilostazol Versus Double-Dose Clopidogrel After Drug-Eluting Stent
Implantation: The HOST-ASSURE Randomized Trial (Harmonizing Optimal Strategy
for Treatment of Coronary Artery StenosisdSafety & Effectiveness of Drug-Eluting
Stents & Anti-platelet Regimen)932Kyung Woo Park, Si-Hyuck Kang, Jin Joo Park, Han-Mo Yang, Hyun-Jae Kang,
Bon-Kwon Koo, Byoung-Eun Park, Kwang Soo Cha, Jay Young Rhew, Hui-Kyoung Jeon,
Eun Seok Shin, Ju Hyeon Oh, Myung-Ho Jeong, Sanghyun Kim, Kyung-Kuk Hwang,
Jung-Han Yoon, Sung Yun Lee, Tae-Ho Park, Keon Woong Moon, Hyuck-Moon Kwon,
In-Ho Chae, Hyo-Soo Kim
Antiplatelet regimen after percutaneous coronary intervention (PCI) is important to
prevent adverse clinical events. This study tested the noninferiority of triple anti-
platelet therapy (TAT) versus double-dose clopidogrel dual antiplatelet therapy
(DDAT) in all-comers undergoing PCI. A total of 3,755 patients were randomized
to TAT or DDAT for 1 month, and the primary outcome was the incidence of net
clinical outcome. TAT was noninferior to DDAT with respect to the primary
outcome (p ¼ 0.0007 for noninferiority). The individual endpoints were also
similar, and there were no signiﬁcant between-group differences. The adjunctive use
of cilostazol in addition to conventional dual antiplatelet therapy showed compa-
rable outcomes and seems to be noninferior to doubling clopidogrel dose for 1
month in all-comers undergoing PCI.
See additional content in the online version of this issue.EDITORIAL COMMENTCilostazoldA Forgotten Antiplatelet Agent, But Does it Even Matter? 943Carl J. Lavie, James J. DiNicolantonioElevated Levels of Systemic Pentraxin 3 Are Associated With Thin-Cap
Fibroatheroma in Coronary Culprit Lesions: Assessment by Optical Coherence
Tomography and Intravascular Ultrasound945Seiji Koga, Satoshi Ikeda, Takeo Yoshida, Tomoo Nakata, Masayoshi Takeno, Nobuhito Masuda,
Yuji Koide, Hiroaki Kawano, Koji Maemura
The present study examined associations between systemic levels of pentraxin 3
(PTX3) and thin-cap ﬁbroatheroma (TCFA) assessed by optical coherence
tomography and intravascular ultrasound in 75 patients with coronary artery
diseases. Levels of PTX3 were signiﬁcantly higher in patients with than in those
without TCFA. Multivariate logistic regression analysis showed that a higher PTX3
level was the most powerful predictor of TCFA. Receiver-operating characteristic
curve analysis showed that >3.24 ng/ml of PTX3 predicted TCFA with 84%
sensitivity and 86% speciﬁcity. In conclusion, PTX3 levels might reﬂect coronary
plaque vulnerability leading to the development of acute coronary syndrome.(continued on A-23)
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A-23Automated 3-Dimensional Aortic Annular Assessment by Multidetector Computed
Tomography in Transcatheter Aortic Valve Implantation955Yusuke Watanabe, Marie-Claude Morice, Erik Bouvier, Tora Leong, Kentaro Hayashida,
Thierry Lefèvre, Thomas Hovasse, Mauro Romano, Bernard Chevalier, Patrick Donzeau-Gouge,
Arnaud Farge, Bertrand Cormier, Philippe Garot
The accuracy, reproducibility, and predictive value for post-procedural aortic
regurgitation (AR) of an automated multidetector row computed tomography
(MDCT) imaging software were evaluated in 105 patients undergoing transcatheter
aortic valve implantation (TAVI). The automated software showed good agreement
with manual MDCT measurements and better reproducibility compared with
manual measurement. In 44 recipients of a self-expanding valve, the valve diameter/
CT-measured mean annulus diameter ratio by automated software showed better
discrimination ability in predicting post-procedural AR. The automated software
demonstrated reliable, reproducible aortic annulus measurement and better
predictive value for post-procedural AR, suggesting important clinical implications
of patients undergoing TAVI.JACC: Cardiovascular Interventions CME is available online.
Go to http://interventions.onlinejacc.org/ to participate.Preparatory Balloon Aortic Valvuloplasty During Transcatheter Aortic Valve
Implantation for Improved Valve Sizing965Polykarpos C. Patsalis, Fadi Al-Rashid, Till Neumann, Björn Plicht,
Heike A. Hildebrandt, Daniel Wendt, Matthias Thielmann, Heinz G. Jakob,
Gerd Heusch, Raimund Erbel, Philipp Kahlert
Valve size selection is currently based on annular measurements by pre-interven-
tional imaging but paravalvular aortic regurgitation (PAR) is a frequent problem.
We evaluated whether supra-aortic angiography during preparatory balloon aortic
valvuloplasty (BAV) improves valve sizing. Data of 270 patients with either
conventional sizing (group 1, n ¼ 167) or BAV-based sizing (group 2, n ¼ 103)
were compared. PAR was observed in 113 patients of group 1 and 41 of group 2
(67.7% vs. 39.8%, p < 0.001). Balloon sizing resulted in selection of the bigger
prosthesis in 30 (29%) patients with borderline annulus size. Preparatory BAV
during transcatheter aortic valve implantation improves valve sizing and reduces
associated PAR.
This article has an accompanying video that can be viewed in the online
version of this issue.EDITORIAL COMMENTTo Size or Not to SizedThere Is No Question: Balloon Sizing for Transcatheter Aortic
Valve Replacement972Vasilis Babaliaros(continued on A-24)
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A-24Prospective Randomized Trial of Transthoracic Echocardiography Versus
Transesophageal Echocardiography for Assessment and Guidance of Transcatheter
Closure of Atrial Septal Defects in Children Using the Amplatzer Septal Occluder974Sergio Bartakian, Howaida G. El-Said, Beth Printz, John W. Moore
We performed a controlled, prospective, randomized study related to the use of
echocardiography in percutaneous atrial septal defect (ASD) closure. In 1 group, we
used transthoracic echocardiography (TTE) to determine Amplatzer septal occluder
(ASO) size and to guide device implant. We compared this group with another that
employed standard TEE-guided assessment and device implant. There was no
difference with respect to defect or device sizes between groups. Procedural success
was 100% in both groups, and there were no major complications. This study
suggests that TTE may be as safe and effective as TEE in defect assessment and
device guidance of ASO implant for ASD closure.IMAGES IN
INTERVENTIONNeurovascular Rescue for Thrombus-Related Embolic Stroke During Transcatheter
Aortic Valve Implantation981Pablo Salinas, Raul Moreno, Remedios Frutos, Jose Luis Lopez-Sendon
This article has an accompanying video that can be viewed in the online
version of this issue.Is This Spontaneous Coronary Intramural Hematoma or Fibrotic Plaque?
An Inconsistent Finding Between Optical Coherent Tomography and
Intravascular Ultrasound983Wei Liu, Yu-Jie Zhou, Yu-Yang Liu, Dong-Mei ShiVisualization of Coronary Plaque Vasa Vasorum by Intravascular Ultrasound 985Teruyoshi Kume, Hiroyuki Okura, Kenzo Fukuhara, Terumasa Koyama, Ryotaro Yamada,
Yoji Neishi, Akihiro Hayashida, Takahiro Kawamoto, Kiyoshi Yoshida(continued on A-25)
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A-25LETTERS TO THE
EDITORChallenges in Retrospective Analysis of PCI Data in Critically Ill Patients 986Ayaka Endo, Atsushi Mizuno, Shun Kohsaka, Kentaro EjiriREPLYDarren Mylotte, Marie-Claude Morice, Hélène Eltchaninoff, Jérôme Garot, Yves Louvard,
Thierry Lefèvre, Philippe GarotAsymptomatic Cerebral Lesions After Carotid Artery Stenting May Not Predict
Future Cerebrovascular Events But May Be Associated With Cognitive
Impairment987Kosmas I. Paraskevas, Athanasios D. GiannoukasREPLYKlaudija Bijuklic, Andreas Wandler, Thilo Tuebler, Joachim SchoferEDITOR’S GUEST
VIEWPOINTHow Do Interventional Cardiologists Make Decisions? Implications for Practice
and Reimbursement989Lloyd W. KleinCORRECTION 992
